JP2020514252A - Ｃｄｋ４／６媒介性がんを治療するための組成物および方法 - Google Patents
Ｃｄｋ４／６媒介性がんを治療するための組成物および方法 Download PDFInfo
- Publication number
- JP2020514252A JP2020514252A JP2019530811A JP2019530811A JP2020514252A JP 2020514252 A JP2020514252 A JP 2020514252A JP 2019530811 A JP2019530811 A JP 2019530811A JP 2019530811 A JP2019530811 A JP 2019530811A JP 2020514252 A JP2020514252 A JP 2020514252A
- Authority
- JP
- Japan
- Prior art keywords
- cdk4
- cancer
- alkyl
- mmol
- heterocyclyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y203/00—Acyltransferases (2.3)
- C12Y203/02—Aminoacyltransferases (2.3.2)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662431806P | 2016-12-08 | 2016-12-08 | |
| US62/431,806 | 2016-12-08 | ||
| PCT/US2017/065027 WO2018106870A1 (en) | 2016-12-08 | 2017-12-07 | Compositions and methods for treating cdk4/6-mediated cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020514252A true JP2020514252A (ja) | 2020-05-21 |
| JP2020514252A5 JP2020514252A5 (enExample) | 2021-01-28 |
Family
ID=62491322
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019530811A Pending JP2020514252A (ja) | 2016-12-08 | 2017-12-07 | Ｃｄｋ４／６媒介性がんを治療するための組成物および方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11541051B2 (enExample) |
| EP (1) | EP3551185A4 (enExample) |
| JP (1) | JP2020514252A (enExample) |
| CN (1) | CN110267659A (enExample) |
| AU (1) | AU2017370694A1 (enExample) |
| CA (1) | CA3045037A1 (enExample) |
| WO (1) | WO2018106870A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023535054A (ja) * | 2020-07-21 | 2023-08-15 | ユービックス セラピューティクス インコーポレイテッド | アンドロゲン受容体分解用化合物及びその医薬用途 |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2968291B1 (en) * | 2013-03-15 | 2025-04-16 | Pharmacosmos Holding A/S | Hspc-sparing treatments for rb-positive abnormal cellular proliferation |
| WO2018005863A1 (en) * | 2016-07-01 | 2018-01-04 | G1 Therapeutics, Inc. | Pyrimidine-based compounds for the treatment of cancer |
| CA3028751A1 (en) | 2016-07-01 | 2018-01-04 | G1 Therapeutics, Inc. | Pyrimidine-based antiproliferative agents |
| CA3041840A1 (en) | 2016-10-28 | 2018-05-03 | Icahn School Of Medicine At Mount Sinai | Compositions and methods for treating ezh2-mediated cancer |
| EP3551185A4 (en) | 2016-12-08 | 2021-07-14 | Icahn School of Medicine at Mount Sinai | COMPOSITIONS AND METHODS OF TREATMENT OF CDK4 / 6 MEDIATED CANCER |
| US11173211B2 (en) | 2016-12-23 | 2021-11-16 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides |
| SG11202000143PA (en) | 2017-07-10 | 2020-02-27 | Celgene Corp | Antiproliferative compounds and methods of use thereof |
| CN109516989B (zh) * | 2017-09-17 | 2021-12-31 | 上海美志医药科技有限公司 | 一类抑制并降解cdk的化合物 |
| JP7569688B2 (ja) | 2017-12-22 | 2024-10-18 | ハイバーセル，インコーポレイテッド | ホスファチジルイノシトールリン酸キナーゼ阻害剤としてのアミノピリジン誘導体 |
| US11472799B2 (en) | 2018-03-06 | 2022-10-18 | Icahn School Of Medicine At Mount Sinai | Serine threonine kinase (AKT) degradation / disruption compounds and methods of use |
| US11358952B2 (en) | 2018-04-23 | 2022-06-14 | Celgene Corporation | Substituted 4-aminoisoindoline-1,3-dione compounds, compositions thereof, and methods of treatment therewith |
| WO2019242625A1 (zh) * | 2018-06-20 | 2019-12-26 | 上海科技大学 | 制备来那度胺衍生物的方法 |
| CA3104298A1 (en) | 2018-06-21 | 2019-12-26 | Icahn School Of Medicine At Mount Sinai | Wd40 repeat domain protein 5 (wdr5) degradation / disruption compounds and methods of use |
| EP3817745A4 (en) * | 2018-07-05 | 2022-04-06 | Icahn School of Medicine at Mount Sinai | PROTEIN TYROSINE KINASE 6 (PTK6) DEGRADATION/DISPUTED COMPOUNDS AND METHODS OF USE |
| WO2020023502A1 (en) * | 2018-07-23 | 2020-01-30 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
| CN108948136A (zh) * | 2018-08-06 | 2018-12-07 | 浙江华海药业股份有限公司 | 一种赖诺普利杂质及其制备方法 |
| CN110835345A (zh) * | 2018-08-17 | 2020-02-25 | 中国科学院上海药物研究所 | 一类细胞周期依赖性激酶的降解剂、其制备方法、药物组合物及其用途 |
| JP7297053B2 (ja) | 2018-08-20 | 2023-06-23 | アルビナス・オペレーションズ・インコーポレイテッド | 神経変性疾患を治療するためのｅ３ユビキチンリガーゼ結合活性を有するキメラ（ｐｒｏｔａｃ）化合物を標的とし、アルファ－シヌクレインタンパク質を標的とするタンパク質分解 |
| MX2021003999A (es) * | 2018-10-08 | 2021-06-23 | Univ Michigan Regents | Moleculas de bajo peso molecular degradadoras de la proteina mdm2. |
| BR122023024103A2 (pt) * | 2018-10-15 | 2024-02-20 | Nurix Therapeutics, Inc. | Compostos bifuncionais para degradação de btk por meio da via de proteossoma de ubiquitina, composição farmacêutica compreendendo os mesmos, e seus usos |
| EP3873906A4 (en) * | 2018-11-02 | 2022-07-27 | The Wistar Institute of Anatomy and Biology | PROTEOLYSIS-TARGETED CHIMERAS |
| US20220016102A1 (en) * | 2018-11-21 | 2022-01-20 | Shanghaitech University | Er protein regulators and use thereof |
| CN113660937A (zh) * | 2019-02-08 | 2021-11-16 | 佛罗里达大学研究基金公司 | 治疗剂和治疗方法 |
| WO2020173440A1 (en) * | 2019-02-27 | 2020-09-03 | Cullgen (Shanghai), Inc. | Cyclic-amp response element binding protein (cbp) and/or adenoviral e1a binding protein of 300 kda (p300) degradation compounds and methods of use |
| MX2021011242A (es) | 2019-03-21 | 2022-01-19 | Codiak Biosciences Inc | Conjugados de vesícula extracelular y usos de estos. |
| US12233356B2 (en) | 2019-03-21 | 2025-02-25 | Lonza Sales Ag | Process for preparing extracellular vesicles |
| CN114269331A (zh) * | 2019-03-28 | 2022-04-01 | 埃萨制药股份有限公司 | 雄激素受体调节剂和用作蛋白水解靶向嵌合体配体的方法 |
| US11485735B2 (en) * | 2019-04-25 | 2022-11-01 | Wuxi Shuangliang Biotechnology Co., Ltd. | Selective CDK4/6 inhibitor and preparation thereof |
| CN114423463B (zh) * | 2019-05-06 | 2025-09-26 | 西奈山伊坎医学院 | 作为hpk1的降解剂的异双功能化合物 |
| CA3142713A1 (en) * | 2019-06-03 | 2020-12-10 | Regents Of The University Of Minnesota | Compounds that degrade kinases and uses thereof |
| TW202112767A (zh) | 2019-06-17 | 2021-04-01 | 美商佩特拉製藥公司 | 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物 |
| CN114867727B (zh) | 2019-07-17 | 2025-02-21 | 阿尔维纳斯运营股份有限公司 | Tau蛋白靶向化合物及相关使用方法 |
| US12491251B2 (en) * | 2019-08-05 | 2025-12-09 | Dana-Farber Cancer Institute, Inc. | Degraders of cyclin-dependent kinase 7 (CDK7) and uses thereof |
| CN112457365B (zh) * | 2019-09-09 | 2023-06-09 | 中国医学科学院药物研究所 | 一类靶向蛋白质水解通路的功能分子及其制备和应用 |
| CA3154386A1 (en) | 2019-10-17 | 2021-04-22 | Michael Berlin | Bifunctional molecules containing an e3 ubiquitine ligase binding moiety linked to a bcl6 targeting moiety |
| IL293940A (en) | 2019-12-16 | 2022-08-01 | Lunella Biotech Inc | Selective cancer drugs cdk4/6 inhibitors |
| EP4077325A4 (en) | 2019-12-16 | 2023-11-15 | Lunella Biotech, Inc. | THERAPEUTIC AGENTS SELECTIVE CDK 4/6 INHIBITORS |
| CA3162266A1 (en) * | 2019-12-17 | 2021-06-24 | Nikolai Kley | Bifunctional agents for protein recruitment and/or degradation |
| JP2023507590A (ja) * | 2019-12-17 | 2023-02-24 | オリオニス バイオサイエンシズ，インコーポレイテッド | タンパク質の動員および／または分解を調節する化合物 |
| EP4090658A4 (en) | 2020-01-15 | 2024-03-13 | University Of Florida Research Foundation, Incorporated | THERAPEUTIC AGENTS AND METHODS OF TREATMENT |
| WO2021150945A1 (en) * | 2020-01-23 | 2021-07-29 | Icahn School Of Medicine At Mount Sinai | Methods of diagnosing and treating cancer |
| ES3048084T3 (en) | 2020-05-19 | 2025-12-09 | Pharmacosmos Holding As | Cyclin-dependent kinase inhibiting compounds for the treatment of medical disorders |
| WO2021237100A1 (en) | 2020-05-21 | 2021-11-25 | Codiak Biosciences, Inc. | Methods of targeting extracellular vesicles to lung |
| US12103924B2 (en) | 2020-06-01 | 2024-10-01 | Icahn School Of Medicine At Mount Sinai | Mitogen-activated protein kinase kinase (MEK) degradation compounds and methods of use |
| AU2021287380A1 (en) * | 2020-06-11 | 2023-01-05 | Lunella Biotech, Inc. | Selective CDK4/6 inhibitor cancer therapeutics |
| WO2022039421A1 (ko) * | 2020-08-18 | 2022-02-24 | 재단법인대구경북과학기술원 | 아베마시클립을 유효성분으로 포함하는 퇴행성 뇌질환의 예방 또는 치료용 약학적 조성물 |
| KR102601028B1 (ko) * | 2020-08-18 | 2023-11-10 | 재단법인대구경북과학기술원 | 아베마시클립을 유효성분으로 포함하는 퇴행성 뇌질환의 예방 또는 치료용 약학적 조성물 |
| US12180193B2 (en) | 2020-08-28 | 2024-12-31 | Arvinas Operations, Inc. | Accelerating fibrosarcoma protein degrading compounds and associated methods of use |
| US20240241020A1 (en) | 2020-09-23 | 2024-07-18 | Lonza Sales Ag | Process for preparing extracellular vesicles |
| CN114349738B (zh) * | 2020-10-14 | 2023-05-05 | 清华大学 | 一类靶向降解cdk2的小分子缀合物及其应用 |
| AR124154A1 (es) | 2020-11-27 | 2023-02-22 | Rhizen Pharmaceuticals Ag | Inhibidores de cdk |
| WO2022149057A1 (en) | 2021-01-05 | 2022-07-14 | Rhizen Pharmaceuticals Ag | Cdk inhibitors |
| CA3208313A1 (en) | 2021-01-13 | 2022-07-21 | Monte Rosa Therapeutics Ag | Isoindolinone compounds |
| AU2022259683A1 (en) | 2021-04-16 | 2023-10-19 | Arvinas Operations, Inc. | Modulators of bcl6 proteolysis and associated methods of use |
| US12377106B2 (en) | 2021-10-26 | 2025-08-05 | Nurix Therapeutics, Inc. | Piperidinylpyrazine-carboxamide compounds for treating and preventing cancer and for degrading BTK |
| KR20240148007A (ko) * | 2021-12-08 | 2024-10-10 | 글루탁스 테라퓨틱스 (상하이) 씨오., 엘티디. | E3 유비퀴틴 리가제 리간드 (ubiquitin ligase ligand) 화합물, 이 리간드 화합물을 기초로 하여 개발된 단백질 분해제 및 이들의 응용 |
| US20230295118A1 (en) * | 2022-03-18 | 2023-09-21 | EnhancedBio Inc. | Compounds and methods for the targeted degradation of cyclin dependent kinases |
| WO2023220640A1 (en) * | 2022-05-10 | 2023-11-16 | Biotheryx, Inc. | Cdk protein degraders, pharmaceutical compositions, and therapeutic applications |
| CN114957249B (zh) * | 2022-05-20 | 2023-04-21 | 东南大学 | 一种不可逆共价结合cdk抑制剂及其制备方法和应用 |
| US11957759B1 (en) | 2022-09-07 | 2024-04-16 | Arvinas Operations, Inc. | Rapidly accelerated fibrosarcoma (RAF) degrading compounds and associated methods of use |
| WO2024056077A1 (en) * | 2022-09-15 | 2024-03-21 | Cullgen (Shanghai) , Inc. | Modified proteins and protein binders and degraders |
| EP4605088A1 (en) * | 2022-10-21 | 2025-08-27 | Novartis AG | Molecular glue degrader compounds and uses thereof |
| CN115650968B (zh) * | 2022-12-27 | 2023-03-21 | 英矽智能科技(上海)有限公司 | 作为cdk选择性抑制剂的新型哒嗪酮化合物 |
| WO2024229287A1 (en) * | 2023-05-03 | 2024-11-07 | St. Jude Children's Research Hospital, Inc. | A sequence selective dna binding molecule (syngrader) |
| CN120981456A (zh) | 2023-05-24 | 2025-11-18 | 金橘生物科技公司 | 杂环化合物及其用途 |
| WO2024256569A1 (en) * | 2023-06-13 | 2024-12-19 | Rijksuniversiteit Groningen | Novel cdk degraders |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5691147A (en) * | 1994-06-02 | 1997-11-25 | Mitotix, Inc. | CDK4 binding assay |
| US20140031325A1 (en) * | 2010-12-06 | 2014-01-30 | Celgene Corporation | Combination therapy with lenalidomide and a cdk inhibitor for treating multiple myeloma |
| US20150274738A1 (en) * | 2012-10-19 | 2015-10-01 | Dana-Farber Cancer, Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6486214B1 (en) | 1997-09-10 | 2002-11-26 | Rutgers, The State University Of New Jersey | Polyanhydride linkers for production of drug polymers and drug polymer compositions produced thereby |
| ATE369359T1 (de) | 2000-02-15 | 2007-08-15 | Sugen Inc | Pyrrol substituierte indolin-2-on protein kinase inhibitoren |
| RS51725B (sr) | 2006-09-15 | 2011-10-31 | Celgene Corporation | Jedinjenja n-metilaminometil izoindola i kompozicije koje ih sadrže i upotreba istih |
| WO2008109104A1 (en) | 2007-03-07 | 2008-09-12 | The Regents Of The University Of California | Bivalent inhibitors of akt protein kinase |
| MX2009014013A (es) | 2007-07-05 | 2010-01-28 | Array Biopharma Inc | Pirimidil ciclopentanos como inhibidores de la proteina cinasa akt. |
| US20110172107A1 (en) | 2008-04-30 | 2011-07-14 | Fox Chase Cancer Center | Assay for identifying agents that modulate epigenetic silencing, and agents identified thereby |
| WO2011029054A1 (en) | 2009-09-04 | 2011-03-10 | The Regents Of The University Of Michigan | Compositions and methods for treatment of leukemia |
| RS56232B1 (sr) | 2010-02-11 | 2017-11-30 | Celgene Corp | Derivati arilmetoksi izoindolina i kompozicije koje ih obuhvataju i postupci njihove primene |
| HK1208875A1 (en) | 2012-01-12 | 2016-03-18 | 耶鲁大学 | Compounds & methods for the enhanced degradation of targeted proteins & other polypeptides by an e3 ubiquitin ligase |
| US20150119435A1 (en) * | 2012-05-11 | 2015-04-30 | Yale University | Compounds useful for promoting protein degradation and methods using same |
| US9604930B2 (en) | 2012-12-21 | 2017-03-28 | Epizyme, Inc. | Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof |
| ES2687477T3 (es) | 2013-12-31 | 2018-10-25 | Xuanzhu Pharma Co., Ltd. | Inhibidor de quinasa y su uso |
| WO2015104677A1 (en) | 2014-01-10 | 2015-07-16 | Piramal Enterprises Limited | Heterocyclic compounds as ezh2 inhibitors |
| MX387318B (es) | 2014-04-14 | 2025-03-18 | Arvinas Operations Inc | Moduladores de la proteólisis basados en imida y métodos de uso asociados. |
| HUE063194T2 (hu) | 2014-06-13 | 2024-01-28 | Bach Biosciences Llc | FAP-aktivált terápiás szerek és az azokkal kapcsolatos felhasználások |
| EP3885343A1 (en) | 2014-11-06 | 2021-09-29 | Dana-Farber Cancer Institute, Inc. | Indole compounds as ezh2 inhibitors and uses thereof |
| WO2016089883A1 (en) | 2014-12-01 | 2016-06-09 | Novartis Ag | Compositions and methods for diagnosis and treatment of prostate cancer |
| JP6815318B2 (ja) * | 2014-12-23 | 2021-01-20 | ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド | 二官能性分子によって標的化タンパク質分解を誘導する方法 |
| WO2016106518A1 (zh) | 2014-12-29 | 2016-07-07 | 深圳市日上光电股份有限公司 | 导线集成式照明灯箱 |
| TWI698436B (zh) | 2014-12-30 | 2020-07-11 | 美商佛瑪治療公司 | 作為泛素特異性蛋白酶７抑制劑之吡咯并及吡唑并嘧啶 |
| EP3244927A1 (en) | 2015-01-16 | 2017-11-22 | Vedantra Pharmaceuticals Inc. | Multilamellar lipid vesicle compositions including a conjugated anaplastic lymphoma kinase (alk) variant and uses thereof |
| CN108601764A (zh) | 2015-03-18 | 2018-09-28 | 阿尔维纳斯股份有限公司 | 用于靶蛋白的增强降解的化合物和方法 |
| US10988737B2 (en) | 2015-04-28 | 2021-04-27 | Universite De Strasbourg | Clinical gene signature-based human cell culture model and uses thereof |
| US10377759B2 (en) | 2015-06-22 | 2019-08-13 | Ono Pharmaceutical Co., Ltd. | Brk inhibitory compound |
| CN105085620B (zh) * | 2015-06-25 | 2018-05-08 | 中山大学附属第一医院 | 一种靶向泛素化降解Smad3的化合物 |
| WO2017007612A1 (en) | 2015-07-07 | 2017-01-12 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| KR20180035828A (ko) | 2015-07-10 | 2018-04-06 | 아비나스 인코포레이티드 | 단백질 분해의 mdm2계 조절인자 및 관련된 이용 방법 |
| BR112017028269A2 (pt) | 2015-07-13 | 2018-09-04 | Arvinas Inc | composto, composição farmacêutica, uso de uma quantidade efetiva de um composto, estado ou condição de doença, e, método para identificar um composto. |
| US9809603B1 (en) | 2015-08-18 | 2017-11-07 | Deuterx, Llc | Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same |
| US20170114098A1 (en) | 2015-09-03 | 2017-04-27 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
| CA3015417A1 (en) | 2016-03-01 | 2017-09-08 | Propellon Therapeutics Inc. | Inhibitors of wdr5 protein-protein binding |
| DK3423451T3 (da) | 2016-03-01 | 2022-11-28 | Propellon Therapeutics Inc | Inhibitorer af wdr5-protein-proteinbinding |
| JP6921115B2 (ja) | 2016-04-22 | 2021-08-18 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | サイクリン依存性キナーゼ４／６（ｃｄｋ４／６）阻害剤のｅ３リガーゼリガンドとのコンジュゲーションによるｃｄｋ４／６の分解および使用法 |
| CN109790143A (zh) | 2016-05-10 | 2019-05-21 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| WO2017197055A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| AR109595A1 (es) | 2016-09-09 | 2018-12-26 | Incyte Corp | Compuestos de pirazolopirimidina y usos de estos como inhibidores de hpk1 |
| US10160763B2 (en) | 2016-09-13 | 2018-12-25 | Vanderbilt University | WDR5 inhibitors and modulators |
| CA3041840A1 (en) | 2016-10-28 | 2018-05-03 | Icahn School Of Medicine At Mount Sinai | Compositions and methods for treating ezh2-mediated cancer |
| EP3551185A4 (en) | 2016-12-08 | 2021-07-14 | Icahn School of Medicine at Mount Sinai | COMPOSITIONS AND METHODS OF TREATMENT OF CDK4 / 6 MEDIATED CANCER |
| US11052091B2 (en) | 2016-12-21 | 2021-07-06 | Ono Pharmaceutical Co., Ltd. | BRK inhibitory compound |
| WO2019113071A1 (en) | 2017-12-05 | 2019-06-13 | Icahn School Of Medicine At Mount Sinai | Compositions and methods for treating alk-mediated cancer |
| EP3755317A4 (en) | 2018-02-22 | 2022-02-23 | Icahn School of Medicine at Mount Sinai | COMPOUNDS DEGRADING/DESTRUCTING PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) AND METHODS OF USE |
| US11472799B2 (en) | 2018-03-06 | 2022-10-18 | Icahn School Of Medicine At Mount Sinai | Serine threonine kinase (AKT) degradation / disruption compounds and methods of use |
| US20210186972A1 (en) | 2018-05-15 | 2021-06-24 | The United States Of America,As Represented By The Secretary,Department Of Health And Human Services | Formulations and methods for the prevention and treatment of tumor metastasis and tumorigenesis |
| CA3104298A1 (en) | 2018-06-21 | 2019-12-26 | Icahn School Of Medicine At Mount Sinai | Wd40 repeat domain protein 5 (wdr5) degradation / disruption compounds and methods of use |
| WO2020252043A1 (en) | 2019-06-10 | 2020-12-17 | Sutro Biopharma, Inc. | 5H-PYRROLO[3,2-d]PYRIMIDINE-2,4-DIAMINO COMPOUNDS AND ANTIBODY CONJUGATES THEREOF |
| US20220274980A1 (en) | 2019-07-30 | 2022-09-01 | The Scripps Research Institute | Pharmacological inhibitors of the enl yeats domain |
| US12103924B2 (en) | 2020-06-01 | 2024-10-01 | Icahn School Of Medicine At Mount Sinai | Mitogen-activated protein kinase kinase (MEK) degradation compounds and methods of use |
| CN112778303A (zh) | 2020-12-31 | 2021-05-11 | 武汉九州钰民医药科技有限公司 | Cdk4/6激酶抑制剂shr6390的制备方法 |
-
2017
- 2017-12-07 EP EP17877800.7A patent/EP3551185A4/en active Pending
- 2017-12-07 AU AU2017370694A patent/AU2017370694A1/en not_active Abandoned
- 2017-12-07 CA CA3045037A patent/CA3045037A1/en not_active Abandoned
- 2017-12-07 JP JP2019530811A patent/JP2020514252A/ja active Pending
- 2017-12-07 WO PCT/US2017/065027 patent/WO2018106870A1/en not_active Ceased
- 2017-12-07 US US16/467,888 patent/US11541051B2/en active Active
- 2017-12-07 CN CN201780085879.6A patent/CN110267659A/zh active Pending
-
2021
- 2021-11-04 US US17/453,619 patent/US20220054488A1/en not_active Abandoned
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5691147A (en) * | 1994-06-02 | 1997-11-25 | Mitotix, Inc. | CDK4 binding assay |
| US20140031325A1 (en) * | 2010-12-06 | 2014-01-30 | Celgene Corporation | Combination therapy with lenalidomide and a cdk inhibitor for treating multiple myeloma |
| US20150274738A1 (en) * | 2012-10-19 | 2015-10-01 | Dana-Farber Cancer, Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023535054A (ja) * | 2020-07-21 | 2023-08-15 | ユービックス セラピューティクス インコーポレイテッド | アンドロゲン受容体分解用化合物及びその医薬用途 |
| JP7557230B2 (ja) | 2020-07-21 | 2024-09-27 | ユービックス セラピューティクス インコーポレイテッド | アンドロゲン受容体分解用化合物及びその医薬用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3551185A4 (en) | 2021-07-14 |
| US20220054488A1 (en) | 2022-02-24 |
| US11541051B2 (en) | 2023-01-03 |
| WO2018106870A1 (en) | 2018-06-14 |
| US20190336503A1 (en) | 2019-11-07 |
| CN110267659A (zh) | 2019-09-20 |
| AU2017370694A1 (en) | 2019-07-25 |
| CA3045037A1 (en) | 2018-06-14 |
| EP3551185A1 (en) | 2019-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020514252A (ja) | Ｃｄｋ４／６媒介性がんを治療するための組成物および方法 | |
| US11345714B2 (en) | Compounds targeting proteins, compositions, methods, and uses thereof | |
| US9187434B2 (en) | Substituted 1,5-benzodiazepinones compounds | |
| JP6473133B2 (ja) | Ｋｒａｓｇ１２ｃの共有結合性阻害剤 | |
| US9273014B2 (en) | Bis(fluoroalkyl)-1,4-benzodiazepinone compounds and prodrugs thereof | |
| US9427442B2 (en) | Fluoroalkyl and fluorocycloalkyl 1,4-benzodiazepinone compounds | |
| JP2021527666A (ja) | Ｗｄ４０反復ドメインタンパク質５（ｗｄｒ５）分解／破壊化合物および使用の方法 | |
| KR20240163107A (ko) | 헤테로환 화합물 및 이의 용도 | |
| JP2022531446A (ja) | Ｈｐｋ１の分解剤としてのヘテロ二官能性化合物 | |
| WO2019113071A1 (en) | Compositions and methods for treating alk-mediated cancer | |
| JP6858984B2 (ja) | がんおよび糖尿病の治療に有用な６−ヘテロシクリル−４−モルホリン−４−イルピリジン−２−オン化合物 | |
| EP3538526A1 (en) | Cyclobutane- and azetidine-containing mono and spirocyclic compounds as alpha v integrin inhibitors | |
| JP7746259B2 (ja) | 核内受容体に対して活性の化合物 | |
| US20150232491A1 (en) | Prodrugs of 1,4-benzodiazepinone compounds | |
| AU2016214492B2 (en) | 2-phenyl-3H-imidazo[4,5-b]pyridine derivates useful as inhibitors of mammalian tyrosine kinase ROR1activity | |
| JP2021529807A (ja) | タンパク質チロシンキナーゼ６（ｐｔｋ６）分解／破壊化合物および使用方法 | |
| KR20240115978A (ko) | Lpa 수용체 길항제 및 이의 용도 | |
| US20020198189A1 (en) | New use | |
| TW202304882A (zh) | 雜環衍生物、醫藥組成物及彼等於治療或改善癌症之用途 | |
| WO2023005894A1 (zh) | 一种Wnt通路抑制剂化合物 | |
| CA3160508C (en) | Substituted ((((6-benzylamino-5-fluoropyrimidin-4-yl)amino)methyl)-piperidin-1-yl)acetamide compounds active towards nuclear receptors | |
| TW202517263A (zh) | 醫藥化合物 | |
| JP2023519603A (ja) | 核内受容体に対して活性な化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201207 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20201207 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20211214 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20220314 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20220516 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220530 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220614 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20220913 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20230124 |